BRCA1 and ovarian neoplasm: Notably, olaparib (which is a PARP inhibitor) represents a targeted therapeutic drug that is currently employed in patients with ovarian tumors harboring BRCA-1 gene mutations, thus yielding favorable clinical outcomes (Figure 6B).